Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma

• Published in: Clinical chemistry and laboratory medicine Vol. 59; no. 2; pp. 353 - 363
• Main Authors: Eisenhofer, Graeme, Deutschbein, Timo, Constantinescu, Georgiana, Langton, Katharina, Pamporaki, Christina, Calsina, Bruna, Monteagudo, Maria, Peitzsch, Mirko, Fliedner, Stephanie, Timmers, Henri J. L. M., Bechmann, Nicole, Fankhauser, Maria, Nölting, Svenja, Beuschlein, Felix, Stell, Anthony, Fassnacht, Martin, Prejbisz, Aleksander, Lenders, Jacques W. M., Robledo, Mercedes
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 23.02.2021; Walter De Gruyter & Company
• Subjects: Catecholamine; Catecholamines; Decision making; Diameters; gene mutations; Metabolites; metanephrines; Mutation; Neuroendocrine tumors; Paraganglioma; Pheochromocytoma; Plasma; Predictions; tumor location; Tumors; VHL protein; pheochromocytoma; gene mutations; metanephrines; tumor location; paraganglioma
• ISSN: 1434-6621; 1437-4331
• DOI: 10.1515/cclm-2020-0904

Plasma free metanephrines are commonly used for diagnosis of pheochromocytoma and paraganglioma (PPGLs), but can also provide other information. This multicenter study prospectively examined whether tumor size, location, and mutations could be predicted by these metabolites. Predictions of tumor location, size, and mutation type, based on measurements of plasma normetanephrine, metanephrine, and methoxytyramine were made without knowledge of disease in 267 patients subsequently determined to have PPGLs. Predictions of adrenal vs. extra-adrenal locations according to increased plasma concentrations of metanephrine and methoxytyramine were correct in 93 and 97% of the respective 136 and 33 patients in who these predictions were possible. Predicted mean tumor diameters correlated positively (p<0.0001) with measured diameters; predictions agreed well for pheochromocytomas but were overestimated for paragangliomas. Considering only patients with mutations, 51 of the 54 (94%) patients with NF1 or RET mutations were correctly predicted with those mutations according to increased plasma metanephrine, whereas no or minimal increase in metanephrine correctly predicted all 71 patients with either VHL or SDHx mutations; furthermore, among the latter group increases in methoxytyramine correctly predicted SDHx mutations in 93% of the 29 cases for this specific prediction. Extents and patterns of increased plasma O-methylated catecholamine metabolites among patients with PPGLs allow predictions of tumor size, adrenal vs. extra-adrenal locations and general types of mutations. Predictions of tumor location are, however, only possible for patients with clearly increased plasma methoxytyramine or metanephrine. Where possible or clinically relevant the predictions are potentially useful for subsequent clinical decision-making.